Search

Compugen Ltd

Atidarymo kaina

2.43 -3.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.41

Max

2.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-65M

-7.7M

Pardavimai

-65M

2.2M

P/E

Sektoriaus vid.

6.158

62.58

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-352.436

Darbuotojai

75

EBITDA

-64M

-7.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+100.8% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-49M

221M

Ankstesnė atidarymo kaina

5.62

Ankstesnė uždarymo kaina

2.43

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-21 23:56; UTC

Fair Isaac Corp shares are higher in after-market trading, supported by positive investor sentiment and a notable rise in the Nikkei 225 Index.

2026-07-21 23:56; UTC

Ulta Beauty Inc. shares are lower in after-market trading, reflecting broader market trends despite positive sentiment from the Nikkei 225 Index surge.

2026-07-21 23:56; UTC

American Electric Power shares are lower in after-market hours, continuing a three-session decline and remaining below the 20-day moving average.

2026-07-21 23:56; UTC

Mondelez International shares declined in after-market trading, continuing a trend of four consecutive lower daily closes despite earlier gains during the session.

2026-07-21 23:56; UTC

Northern Trust shares are higher in after-market trading, reflecting broader positive trends in regional equity indices and renewed investor optimism.

2026-07-21 23:56; UTC

Dorian LPG Ltd shares are trading higher in after-market hours, reflecting a gradual increase since Tuesday's close amid broader positive trends in regional equity indices.

2026-07-21 23:56; UTC

Macro News
ETF Constituents
Correlated Moves

U.S. stock markets rebounded, with the Financial Select Sector SPDR Fund roughly flat in after-hours trading, supported by contributions from SCHW, ICE, FISV, AON, and AXP.

2026-07-21 23:56; UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

2026-07-21 23:56; UTC

Phillips 66 shares are higher in after-market trading, with no specific news identified. Broader market momentum reflects positive investor sentiment amid easing geopolitical tensions.

2026-07-21 23:56; UTC

Shake Shack Inc. shares are higher in after-market trading, reflecting a modest gain amid positive sentiment from broader market trends, including a rise in the Nikkei 225 Index.

2026-07-21 23:56; UTC

Diamondback Energy Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. Trading has reflected overall weaker performance without specific news.

2026-07-21 23:56; UTC

Lumen Technologies Inc. shares are higher in after-market hours, reflecting a modest gain amid broader market weakness and positive sentiment in regional equity indices.

2026-07-21 23:56; UTC

Baidu Inc. shares declined in after-market trading, retracing from an early session peak and remaining below recent averages. No specific news was identified.

2026-07-21 23:56; UTC

Southern Copper Corp shares are lower in after-market trading, retracing from earlier gains while remaining above their 20-day moving average.

2026-07-21 23:56; UTC

Entegris Inc shares are higher in after-market trading, reflecting a notable gain since Tuesday's close amid positive sentiment in regional equity indices.

2026-07-21 23:56; UTC

ETF Constituents

Health Care Select Sector SPDR Fund declines after market close, driven by negative returns from Merck, Amgen, and Eli Lilly. The ETF remains near its one-month trading range.

2026-07-21 23:52; UTC

Kratos Defense shares are higher in after-market trading, rebounding from earlier losses despite no specific news to explain the movement.

2026-07-21 23:51; UTC

Japan's Trade Deficit Expected at -120 Billion Yen Amid Ongoing Economic Challenges and Investor Caution.

2026-07-21 23:51; UTC

Japan's June export growth forecasted at 0.186%, crucial for GDP amid stable market expectations and global supply chain challenges.

2026-07-21 23:51; UTC

Brazil's Central Bank Signals Potential Interest Rate Cuts Amid Lower Inflation Expectations Ahead of Key COPOM Meeting on July 27, 2026.

2026-07-21 23:51; UTC

iShares Core U.S. Aggregate Bond ETF is trading higher in after-market hours amid a general upward trend in global equity indices and positive sentiment in fixed income.

2026-07-21 23:51; UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

2026-07-21 23:51; UTC

Yum China Holdings Inc. shares rose in after-market trading, buoyed by positive market sentiment following earnings reports from Tesla and Broadcom.

2026-07-21 23:51; UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

2026-07-21 23:51; UTC

Zeta Global Holdings is higher in after-market trading, amid broader market strength following positive earnings from companies like Tesla and Broadcom.

2026-07-21 23:51; UTC

Intercontinental Exchange Inc shares are higher in after-market hours amid increased trading activity, remaining above their 20-day moving average and near a one-month high.

2026-07-21 23:51; UTC

Coca-Cola Europacific Partners PLC shares are lower in after-market hours amid notable volatility, with no specific company news identified to explain the movement.

2026-07-21 23:51; UTC

Starwood Property Trust shares rose in after-market trading amid positive market sentiment following earnings reports from companies like Tesla and Broadcom.

2026-07-21 23:51; UTC

NetEase Inc. shares are higher in after-market trading, reflecting positive sentiment from recent earnings reports of firms like Tesla and Broadcom.

2026-07-21 23:51; UTC

Correlated Moves

Nexgen Energy Ltd shares advanced in after-market trading, buoyed by positive sentiment following earnings reports from major companies like Tesla and Broadcom.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

100.8% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  100.8%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat